Mimetogen Pharmaceuticals Inc. Appoints Kim Brazzell, Ph.D. as Chief Medical Officer

Mimetogen Pharmaceuticals Inc. today announced that it has appointed ophthalmic industry veteran Kim Brazzell, Ph.D. as Chief Medical Officer. Dr. Brazzell will lead the development of Mimetogen’s MIM-D3 pivotal program for the treatment of dry eye. The Company previously announced in June of 2011 that MIM-D3, a small molecule TrkA agonist, had successfully completed a 150-patient, multi-center Phase 2 trial for the treatment of dry eye, demonstrating significant improvements in signs and symptoms of the disease and an excellent safety profile.

“MIM-D3 is an exciting molecule with a unique mechanism of action that addresses several of the key causes and sequelae of dry eye disease,” said Kim Brazzell, Ph.D., Chief Medical Officer. “This product differentiation and the strength of the Phase 2 data package, with significant improvements in both signs and symptoms of the disease, position MIM-D3 as an important entrant to the blockbuster field of dry eye. I look forward to working with the team at Mimetogen to advance MIM-D3 into a pivotal program.”

“Dr. Brazzell’s leadership in the successful development of a number of FDA-approved ophthalmic products is ideally suited to the significant potential of the MIM-D3 program and we look forward to his contributions to Mimetogen and the development of MIM-D3,” said Garth Cumberlidge, Ph.D., President and Chief Executive Officer of Mimetogen.
Dr. Brazzell brings more than 20 years of experience in the ophthalmic pharmaceutical industry to Mimetogen. Previously, he held several executive positions at Inspire Pharmaceuticals, including Executive Vice President, Medical and Scientific Affairs, Executive Vice President and Head, Ophthalmology Business and Senior Vice President of Ophthalmic Research and Development. Prior to joining Inspire, he served as Global Head of Clinical R&D and Senior Vice President, U.S. R&D, of Novartis Ophthalmics. He has extensive experience in the discovery and development of multiple successful ophthalmic products including Visudyne®, Zaditor®, RESCULA® and Betoptic S®. In addition to managing the global clinical R&D group for Novartis Ophthalmics, Dr. Brazzell built and managed the U.S.-based R&D group for Ciba Vision Ophthalmics, while serving as their Vice President, R&D, and served as Associate Director, R&D, at Alcon Laboratories, Inc. Dr. Brazzell received a B.S. in pharmacy and a Ph.D. in pharmaceutical sciences from the University of Kentucky.

About MIM-D3
MIM-D3, is a small molecule mimetic of nerve growth factor (NGF) that binds specifically to the TrkA receptor. NGF is a naturally occurring protein in the eyes that is responsible for the maintenance of corneal nerves and epithelium, mucin and tear production. In contrast to most other products in development or on the market, MIM-D3 is designed to quickly and directly improve the quality of the tears produced by the eyes while also reducing clinical signs and symptoms of dry eye, such as chronic dryness and grittiness. MIM-D3 recently completed a Phase 2 randomized, double-masked, multi-center, placebo-controlled trial designed to evaluate the safety, tolerability and efficacy of MIM-D3 in improving both the signs and symptoms of dry eye. The Company reported top line results from the study in June of 2011 in which MIM-D3 demonstrated significant improvements (p≤0.05) in signs and symptoms of dry eye with both low (1%) and high (5%) doses and presented excellent safety and tolerability profiles. Mimetogen is in the process of completing its analysis of the data and intends to present further details at a future medical conference.

About Mimetogen Pharmaceuticals
Mimetogen Pharmaceuticals, Inc. is a private company focused on developing the use of peptidomimetics as a novel approach to treating ophthalmic diseases with high unmet medical needs. The underlying technology was developed at McGill University and the Lady Davis Institute for Medical Research in Montréal. The Company is currently developing novel therapeutic approaches for indications including dry eye disease, glaucoma and other degenerative diseases of the retina.